Tag Archive for: Medical Devices

Jeremy Miller, MD, Joins EndoChoice – Pathology Director

Former Director of Urologic Pathology/GI Pathology at Ameripath

Life Science Partner has recruited Jeremy Miller, MD, to lead the Pathology Lab at EndoChoice, a College of American Pathology (CAP) accredited lab focused on providing the highest level of quality and service to the GI community.

Miller joins EndoChoice after serving as Director of Urologic Pathology and GI Pathology at Ameripath, in addition to formerly serving as Chief Medical Officer for Platinum Pathology, a national GI and GU lab owned by Miller based out of Virginia.

“Miller has excellent training as a pathologist with broad surgical pathology training, he has worked directly under internationally-renowned Dr. Fenoglio-Preiser, one of the top GI leaders in the field,” states Tom Callaway, MD, President and Founder of Life Science Partner.  “He is an entrepreneurial leader in the field of high volume pathology with a can-do attitude that will fit with the corporate culture of EndoChoice.”

Miller earned a Bachelor of Science Degree in Engineering from Duke University and his MD from the Medical College of Georgia.  Miller completed his Fellowship in Genitourinary Surgical Pathology from the The Johns Hopkins Hospital.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Robert Rajalingam Joins Smiths Medical as VP, Global Product Management, Vascular Access

Former Site Leader and Vice President for Global Marketing at Medtronic/Covidien Vascular Therapies

As a medical device leader and strategic marketing executive, Robert Rajalingam has been selected to lead Smith Medical’s $300 M Vascular Access business.

Life Science Partner collaborated closely with Vice President, Carl Stamp to recruit Rajalingam from Medtronic.

Vascular medicine has been his passion and interest, having worked both in the venous therapy area (spearheading the re-branding with Rethink Varicose Veins campaign including an Olympic spokesperson at Covidien) and in arterial disease at Medtronic Vascular in business development, including a partnership with Abbott Vascular.

“Robert is passionate and articulate about medical devices and their ability to improve patient lives. Experienced in managing a maturing product portfolio while simultaneously spearheading product innovation, he has the know-how, tenacity, and marketing instincts to build highly effective teams at Smiths Medical,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Rajalingam earned his Bachelor of Science in Engineering degree from Duke University and his MBA from Stanford Graduate School of Business.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Bill Bold Joins Vestagen Technical Textiles as Chief Executive Officer

Former President and Chief Executive Officer of Vascular Pathways

Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.

Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.

“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.

Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.

Bold earned a Bachelor of Science Degree in Marketing from West Chester University.

Learn More About Life Science Partner

Click button below to find out more about how we recruit Chief Executives:

Learn More About Chief Executive Functions
/0 Comments/by

Abiomed to Appoint Seth Bilazarian, M.D., New Vice President of Interventional Cardiology Programs

DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Seth Bilazarian, M.D. will be appointed as Vice President of Interventional Cardiology Programs, effective October 8, 2015.

“We are excited to welcome Dr. Seth Bilazarian to Abiomed, where he will add a specialized interventional cardiology perspective to the executive team that will further strengthen our mission to recover hearts and save lives. Seth has over 20 years of experience practicing interventional cardiology in the cath lab and has developed an expertise in hemodynamic support. His insight and knowledge will richly enhance our ongoing training and education initiatives for the new standard of care,” said Michael R. Minogue, President, Chairman and Chief Executive Officer, Abiomed.

“I am thrilled to become part of the Abiomed team. As a user, I am very familiar with the benefits of Impella and know it is transforming the standard of care in treating complex patients. I am eager to collaborate with expert and experienced physician users in interventional cardiology and heart failure to develop best practices for use of the Impella platform in Protected PCI,” said Seth Bilazarian, M.D.  “Educating physicians more broadly on the safe, effective and appropriate use of this technology will also be a focus. I am equally enthusiastic about the opportunity to begin working with industry colleagues to bring new devices within the Impella platform to market and continue the collaborative mission of recovering hearts.”

Dr. Bilazarian is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center and Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. Most recently, he was the Director of Clinical Cardiology Research Program and Clinical Cardiologist at Pentucket Medical Associates, LLC. He also serves on the faculty as an instructor in medicine at Harvard Medical School, where he has taught since 1995 and is the founder and director of the largest community based cardiac research program in the Partner’s network.

Dr. Bilazarian is board certified in cardiovascular medicine, nuclear cardiology, vascular ultrasound, interventional cardiology, and vascular and endovascular medicine. Dr. Bilazarian is an active participant in outpatient clinical trials in congestive heart failure, hypertension, heart disease prevention, diabetes, anemia, atrial fibrillation, anti-inflammatory strategies for vascular prevention and anticoagulation and anti-platelet therapies. In 2008, he was appointed as physician advisor to the cardiac device panel of the Food & Drug Administration.

In addition to his clinical practice, Dr. Bilazarian is an active blogger in the physician community. His blog, “Practitioner’s Corner with Dr. Seth Bilazarian” was established in 2009 and is hosted on theheart.org and MedScape (http://goo.gl/k5lZqA). He has written over 100 blog posts that cover various topics across the wide spectrum of interventional cardiology.

Dr. Bilazarian received a Bachelor of Science in Engineering in Chemical Engineering from Tufts University and MD from University of Massachusetts Medical School. He completed his internship and residency at The Johns Hopkins Hospital in Baltimore, and cardiology and interventional cardiology fellowship at Boston University Hospital and Boston City Hospital.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding our expectation of a smooth transition to a new Vice President and Chief Financial Officer, the Company’s expectations of continued commercial growth, and future opportunities, including the opportunity to become the standard of care.

The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K.

Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For more information, please contact:

Aimee Genzler
Director, Corporate Communications
978-646-1553
agenzler@abiomed.com

Ingrid Goldberg
Director, Investor Relations
igoldberg@abiomed.com
/0 Comments/by

Upayan SenGupta, MBA, Recruited to Become Vice President, General Manager, Health Sciences for Underwriters Laboratories

Former Director, Global Segmentation Program, GE Healthcare

Life Science Partner recruited Upayan SenGupta, MBA, an innovative senior medical device executive, to become Vice President and General Manager, Health Sciences for Underwriters Laboratories where he will lead The Company’s continued transformation of the Health Sciences business unit from a compliance and audit organization to a proactive participant in the registration and product development teams.

With over 15 years at GE Healthcare, SenGupta was most recently appointed to create and lead the newly formed Segmentation program focused on cutting-edge big data analytics to drive deeper customer centric process and product design.

During his tenure at GE, SenGupta strategically led partnerships across the Sales, Marketing and Supply Chain teams to simplify product offerings and cut costs to improve targeted solutions for customers worldwide. Throughout his career at GE, SenGupta provided innovative cross-functional leadership to The Company’s operations strategy, product development, supply chain planning and commercial operations.

“With a background in “internal consulting” to develop global manufacturing efficiencies and building new quality systems in one of the world’s largest healthcare products companies, SenGupta will be a major asset in his new role at Underwriters Laboratories,” stated Tom Callaway, MD, President and Founder of Life Science Partner.

SenGupta earned a Bachelor of Science Degree in Electrical and Computer Engineering with a minor in Economics from Purdue University and received his MBA from Northwestern University’s Kellogg School of Management.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Learn More About Chief Executive Functions
/0 Comments/by

Barb DeBaun, RN, MSN Recruited to Vestagen as Consulting Vice President, Clinical Affairs

Improvement Advisor for Cynosure Health Joins Vestagen

Life Science Partner recruited Barb DeBaun, RN, MSN, CIC, to become Vice President, Clinical and Regulatory Affairs for Vestagen Technical Textiles, Inc.

DeBaun joins Vestagen after serving as an Improvement Advisor for Cynosure Health where she provided vision and leadership in the development, implementation and facilitation of performance improvement initiatives for healthcare organizations.

In her new role at Vestagen, DeBaun will serve as the senior clinical leader for The Company overseeing clinical direction, product strategy, medical affairs and key thought leader development. “DeBaun’s passion for protecting the healthcare worker from infection while providing quality care makes her a natural fit for Vestagen’s VP of Clinical and Regulatory Affairs,” states Tom Callaway, MD, Founder and President of Life Science Partner.

DeBaun earned her Bachelor of Science in Nursing from Pace University and her Master of Science in Nursing from San Francisco State University. DeBaun is an active member of APIC having served as the chair of the 2012 APIC Annual Conference Committee and as a member of the APIC Education Committee and the APIC Practice Guidance Council. In 2008, she was selected as Infection Control Today‘s Educator of the Year.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Jim Schneider, JD, Joins American Medical Systems as Manager of Compliance

Former Senior Business Process Analyst, Global Compliance at Boston Scientific

Life Science Partner recruited Jim Schneider, JD to become Manager of Compliance for American Medical Systems, a subsidiary of Endo Health Solutions.

In his new role at AMS, Schneider will have strong business and sales facing responsibilities including training, investigations and the development of new policies across various sales organizations.

Schneider joins AMS after serving as the Senior Business Analyst for the Global Compliance department at Boston Scientific where he was a key member of the team that implemented the first annual CIA Arrangements Audit.

“Smart, engaging, and incredibly resourceful, Schneider has the capability to get the job done under complex circumstances,” states Thomas Callaway, MD, President of Life Science Partner. “He is an excellent communicator and a ‘lead-by-example’ type of manager.”

Schneider earned his Bachelor of Arts in Political Science from Bemidji State University and his Master of Art in Administration and Business Management from Hamline University. He received his Juris Doctor from the William Mitchell College of Law.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

David Gill Joins EndoChoice as Chief Financial Officer

Former Chief Financial Officer at INC Research 

Life Science Partner recruited David Gill, MBA to become Chief Financial Officer at EndoChoice. EndoChoice an Atlanta-based company providing physicians with gastrointestinal endoscopy, diagnostics, infection control and imaging products.

David Gill

He was most recently CFO of INC Research, a publicly traded contract research organization. Previously Gill served as the CFO for TransEnterix, leading a $55 M Series B financing, relocating the company headquarters, and leading planning to scale up GMP manufacturing. As CFO for CTI Molecular Imaging, he raised a total of $213 M including an initial public offering to finance the rapid growth. He established a strategic relationship with Siemens that led to the acquisition of the CTI for $1 B.

In his new role at EndoChoice, Gill will work closely with CEO Mark Gilreath to oversee all corporate financial operations. “Gill understands how to use debt, public markets, and private equity to generate significant return for shareholders,” stated Tom Callaway, MD, Founder and President of Life Science Partner. “He has excelled in companies with highly varied technologies and global operations.”

Gill earned his Bachelor Degree in Accounting from Wake Forest University and his MBA from Emory University Goizueta Business School.

Learn More About Chief Executive Functions
/0 Comments/by

Frank Rivas, JD, Joins American Medical Systems as Compliance Officer

Former Vice President, Compliance and Integrity Programs for NSF Health Sciences

Life Science Partner recruited Frank Rivas, JD to become Compliance Officer for American Medical Systems, a subsidiary of Endo Health Solutions. 

Rivas was previously the Vice President, Chief Compliance Officer of Spectranetics Corporation, an interventional cardiology medical device company under a Corporate Integrity Agreement with the Office of Inspector General of the Health and Human Services.

Most recently Rivas was the Vice President, Compliance and Integrity Programs for NSF Health Sciences, a consulting firm in the field of compliance and corporate integrity.

“Rivas has the leadership background of building a team under the pressure of a DOJ investigation and a CIA,” states Tom Callaway, MD, President of Life Science Partner.  “Rivas has the concise communication skills and gravitas that can only come with experience.”

Rivas earned his Bachelor of Science degree in Marine Science from the United States Merchant Marine Academy and he received his JD from Washburn University in Topeka.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Nigel Wilkinson Joins EndoChoice as Vice President, Quality and Regulatory

Former Senior Vice President, Quality and Assurance at Smith & Nephew

Life Science Partner recruited Nigel Wilkinson, a seasoned quality assurance executive to become the Vice President, Quality and Regulatory for EndoChoice.

In his new role, Wilkinson will be responsible for managing a global quality and regulatory organization in the United States, Germany, and Israel. Wilkinson will report to the Chief Executive Officer, Mark Gilreath.

“Smart. Polished. Articulate.  I believe that Wilkinson is the prototype of the senior quality and regulatory leader,” states Tom Callaway, MD, President of Life Science Partner.  “He has built and led a global quality affairs organization and has extensive track record of achieving business objectives while successfully balancing regulatory requirements.”

Prior to his new position at EndoChoice, Wilkinson spent much of his career at Smith & Nephew where he played a critical role in merging the new Advanced Surgical Devices Division with the previous Orthopedic and Endoscopy Divisions.

Wilkinson earned his Bachelor of Science Degree in Microbiology and Genetics from the University of London, England.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by